✨
AI Summary
- PhenoNet's inhaled Alzheimer's drug, PHENOGENE-1A, cleared for Phase 3 trials.
- Trial will test cromolyn sodium's efficacy in both APOE4 carriers and non-carriers.
- Focus on reducing amyloid aggregation, inflammation, and microglial dysfunction for broader benefit.